ReviewMolecular biology reports2026
Functional dynamics of lncRNAs and miRNAs in cancer metabolism and neuroinflammation.
Review in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Epigenetic pacemaker: A review of DNA methylation, histone lactylation, and non-coding RNAs in autoimmune skin diseases.Journal of translational autoimmunity · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-coding RNAs (ncRNAs) influence gene expression and diverse physiological and pathological processes. Long non-coding RNAs (lncRNAs) and microRNAs (miRNAs) play roles in cancer and neurodegenerative diseases. LncRNAs, such as HOTAIR, MALAT1, and NEAT1, regulate chromatin remodeling through histone modification. Dysregulated expression leads to oncogenesis and neuronal dysfunction. Conversely, miRNAs such as miR-21 and miR-155, as post-transcriptional regulators, act in oncogenic signaling and neuroinflammation. MiR-21 targets PTEN and PDCD4, leading to aberrant activation of the PI3K/AKT and NF-κB pathways, thereby promoting cancer cell proliferation, while influencing neuronal apoptosis and neuroprotection. Similarly, miR-155 modulates SHIP1 and SOCS1 through AKT and JAK/STAT pathways in both cancer and neurodegenerative contexts. The convergence of these signaling cascades reveals a shared molecular framework that links tumor progression to neurodegeneration. Understanding the intricate lncRNA-miRNA-mRNA regulatory networks provide valuable insights into disease mechanisms and clinical applications regarding ncRNAs as biomarkers. Further research integrating transcriptomics, functional genomics, and therapeutic delivery systems is essential to harness the full diagnostic and therapeutic potential of ncRNAs.
Indexed as
Identifiers
42142294What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.